Q-omics provides the consensus-scored HCAR2 profile across patient tissues and cancer cell-line models. HCAR2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, HCAR2 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, HCAR2 RNA expression shows 18,867 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight ACC, THCA, and PDAC as cancer lineages where HCAR2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HCAR2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HCAR2 survival associations across molecular data types. HCAR2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HCAR2 RNA expression–survival associations across cancer types. High HCAR2 expression shows unfavorable associations in ACC, KIRC, UVM, THCA and LGG, but favorable associations in UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .008). Together, the overview and detailed table identify ACC as the clearest survival context for HCAR2 RNA expression.
This table summarizes HCAR2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for HCAR2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HCAR2 shows lower tumor expression in BRCA and LUAD and higher tumor expression in THCA, KICH, BLCA and COAD. The THCA box plot shows higher HCAR2 RNA expression in tumor versus normal tissue (log2 FC = +0.779, t-test p < 0.001).
This table shows molecular features associated with HCAR2 in patient tissues and cancer cell lines. In patient samples, HCAR2 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, HCAR2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in SKIN and URINARY_TRACT.
